Serotonin receptors and their function in sleep, anxiety disorders and depression

Psychotherapy and Psychosomatics

Volumn 65, Issue 2, 1996, Pages 66-75

  Leonard, B E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Anxiety disorder; Depression; Receptor sub types; Schizophrenia; Serotonin; Sleep

Indexed keywords

NEUROTRANSMITTER; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN RECEPTOR;

ANXIETY NEUROSIS; CLONING; DEPRESSION; HUMAN; REVIEW; SCHIZOPHRENIA; SLEEP;

EID: 0029918763     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000289049     Document Type: Article

References (75)

1. Erspamer V, Asero B: Identification of enter-amine, the specific hormone of the cnterochro-maffin cell system, as 5-hydroxytryptamine. Nature 1952:169:800-801.
2. Twarog BM. Page IH: Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol 1953;175:157-161.
3. Amin AH, Crawford TBB. Gaddum HH: The distribution of substance P and 5-hydroxy-tryptaminc in the central nervous system of the dog. J Physiol 1954:126:596-618.
4. Dahlstrom A, Fuxe K: Evidence for the existence of monoamine containing neurons in the central nervous system. Acta Physiol Scand 1964;62(suppl 232): 1-55.
5. Steinbusch HWM: Distribution of serolonin-immunoreactivity in the central nervous system of the rat cell bodies and terminals. Neuroscience 1981;6:557-618.
6. Hover D: Agonists and antagonists at 5HT receptor subtypes. Adv Biosci 1992;85:29-47.
7. Pazos KA. Engel G. Palacios JM: Beta-adrenoceptor blocking agents recognize a sub-population of serotonin receptors in ral brain. Brain Res 1985:343:403-408.
8. Gaddum HH. Picarelli ZP: Two kinds of trypt-amine receptor. BrJ Pharmacol 1957;12:323-328.
9. Engel G, Hover D. Kaikman HO. Wick MB: Pharmacological similarity between the 5HTlD-receptor on the guinea pig ileum and the 5-HT binding site. BrJ Pharmacol 1985:84: 1515-1520.
10. Bradley PB. Engel G. Fcniuk W. Fozard JR, Humphrey PPA. Middlemiss DN. Mylecha-ranc EJ, Richardson BP. Saxena PR: Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptaminc. Neuropharmacology 1986;25:563-576.
11. Dumuis A. Bouhelal R. Sebbcn M. Cory R. Bockaert J: A non-classical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mo-lec Pharmacol 1988:34:880-887.
12. Dumuis A, Sebbcn M, Bockaert J: The gastrointestinal prokinetic benzamidc derivatives are agonists at the non-classical 5HT (5HT4) positively coupled to adenylate cyclase in neurons. NS Arch Pharmacol 1989:340:403-410.
13. Hoyer D: Agonists and antagonists at 5HT receptor subtypes. Adv Biosci 1992:85:29-47.
14. Humphrey P. Hover D. Hamon M: The classification of 5-hydroxytryptaminc receptors. Serotonin Club Nomenclature Committee. Update No. 1. 1989.
15. Glennon RA. Dukat M: Serotonin receptor sub-types; in Bloom FE. Kupfer DJ (cds): Psv-chopharmacology: The Fourth Generation of Progress. New York. Raven Press. 1995, pp 415-430.
16. Bocken J. Ford JR. Dumuis A, Clarke DE: The 5HT4 receptor: A place in the sun. Trends Pharmacol Sei 1992:13:141-145.
17. McGinty DJ. Harper RM: Dorsal raphe neurons: Depression on firing during sleep in cats. Brain Res 1976:101:569-575.
18. Jacob BL. Fornal CA: Serotonin and behaviour: A general hypothesis; in Bloom FE. Kupfer DJ (cds): Psychopharmacology: The Fourth Generation and Progress. New York, Raven Press. 1995, pp 461-469.
19. Koella WP: Serotonin and sleep: in Osborne NN. Hamon M (cds): Neuronal Serotonin. New York. Wiley. 1988. pp 153-170.
20. Pastel RH: Effects of LY53857, a selective 5HT2 antagonist, on sleep in the rat. Soc Neu-rosci Abstr 1988:14:1307.
21. Wilkinson LOL. Dourish CT: Serotonin and animal behaviour, in Peroutka SJ (ed): Serotonin Receptor Sub-Types: Basic and Clinical Aspects. New York. Wiley-Uss. 1991. pp 147-210.
22. Dugovic C. Wauquier A. Lcyscn JE, Mar-rannes R. Janssen PAJ: Functional role of 5HT2 receptors in the regulation of sleep and wakefulness in the rat. Psvchopharmacologv 1979;97:436-442.
23. Hoppenbrouwers ML. Vanden Busschc G. Geldern Y: Is ritanserin a serotonin receptor blocker able to counteract jet lag? A placebo controlled pilot investigation. Psvchopharma-cology 1988:96(suppl):245.
24. Dugovic C. Leysen LE. Janssen PFM. Wau-quicr A: The Iight/dark cycle modulates the effects of ritanserin on sleep wakefulness patterns in the rat. Pharmacol Biochcm Behav 1989:34:533-537.
25. Jacobs BL: Hallucinogens: Neurochcmical. Behavioural and Clinical Perspectives. New York, Raven Press. 1984.
26. Glennon RA: Involvement of serotonin via the action of hallucinogenic agents; in Green AR (cd): Neuropharmacology of Serotonin. London. Oxford University Press. 1985. pp 253-280.
27. Glennon RA: Site selective serotonin agonists and discriminative stimuli: in Colpaert FC. Balster RL (cds): Transduction Mechanisms of Drug Stimuli. Berlin. Springer. 1988.
28. Junien JL, Leonard BE: Review: Drugs acting on sigma and phencyclidine receptors: A review of their nature, function and possible importance. Clin Neuropharmacol 1989:12:353-374.
29. Gill K. Amit Z: Serotonin uptake blockers and volunatary alcohol consumption: A review of recent studies: in Galanter M (ed): Recent Developments on Alcoholism. New York. Plenum Press. 1989. pp 225-248.
30. Myers RD. Quarlford SQ: Alcohol drinking attenuated by sertraline in rats with 60HDA or 5,7 DHT lesions of the N. accumbens: A caloric response. Pharmacol Biochem Behav 1991:40: 923-928.
31. Sellers EM. Higgins GA. Sobell MG: 5-HT and alcohol abuse. Trends Pharmacol Sci 1992:13: 69-75.
32. Collins DM. Myers RD: Buspirone attenuates volitional alcohol intake in chronically drinking monkeys. Alcohol 1984;4:49-56.
33. Mecrt TF: Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. Alcohol Alcohol 1993:28: 157-170.
34. Kilpatrick GJ. Buncc KT. Tyers MB: 5HT3 receptors. Med Res Dev 1990; 10:441-475.
35. Di Chiara G. Impreto A: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Nat Acad Sci USA 1988:85:5274-5278.
36. Carboni E. Aqua E. Frau R. Di Chiara G: Differential inhibitory effects of a 5HT3 antagonist on drug induced stimulation of dopamine release. EurJ Pharmacol 1989:164:515-519.
37. Meltzer HY: Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psycho-pharmacologv 1985;99:S 18-S27.
38. Roth BL, Craigo SC. Chondharv MS: Binding of typical and atypical antipsychotic agents to 5HT6 and 5HT7 receptors. J Pharmacol Exp Ther 1994:268:1403-1410.
39. Meltzer HY, Matsubara S. Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of DI. D2 and 5HT2 pKi values. J Pharmacol Exp Ther 1989;251:238-246.
40. Glennon RA: Involvement of serotonin in this action of hallucinogenic agents: in Green AR (ed): Neuropharmacology of Serotonin. Oxford, Oxford University Press, 1985. pp 253-280.
41. Mita T. Hanada S. Nishino N. Juno T. Nakai H. Yamadori T. Mizoi Y, Tanaka C: Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 1986;21:1407-1414.
42. Hagan RM. Butler A. Hill JM. Jordan CC, Ireland SJ.TyersMB: Effects of the 5HT3 antagonist GR 38032F on responses to injection of a neurokinin agonist into the ventral segmental area of the rat brain. Eur J Pharmacol 1987: 138:303-305.
43. Costall B, Naylor RJ. Tyers MB: Recent advances in the neuropharmacology of 5HT3 agonists and antagonists. Rev Neurosci 1988:2: 41-65.
44. Abbott A: 5HT3 antagonists and ligands for dopamine Dl and autoreceptors offer new leads for antipsychotic drugs. Trends Pharmacol Sci 1990:11:49-51.
45. Tricklebank MD: Interactions between dopamine and 5HT3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 1989:10:127-129.
46. Sleight AJ. Perce PA. Schmidt AW, Hekmatpa-nah CR, Peroutka SJ: The clinical utility of serotonin receptor active agents in neuropsychiatrie disease: in Peroutka S (cd): Serotonin Receptor Sub-Types: Basic and Clinical Aspects. New York, Wiley-Liss, 1991. pp 211-227.
47. Gardner CR: Potential use of drugs modulating 5HT activity in the treatment of anxiety. Gen Pharmacol 1988;19:347-356.
48. Traber J. Galser T: 5HTIA receptor related anxiolytics. Trends Pharmacol Sci 1987:8:432-437.
49. Dourish CT: Brain 5HTIA receptors and anxiety: in Dourish CT. Ahlenius S. Hudson PH (eds): Brain 5HT1A Receptors. Chichester, Horwood. 1987. pp 261-277.
50. Gardner CR: Recent developments in 5HT related pharmacology of animal models of anxiety. Pharmacol Biochcm Behav 1986:24: 1479-1485.
51. Cculemans D, Hoppenbrouwers M. Gcldcrs Y. Reyntjens AJM: The influence of ritanserin, a serotonin antagonist, in anxiety disorders: A double-blind placebo-controlled study vs. lorazépam. Pharmacopsvchiatry 1985:18:303-305.
52. Deakin JFW. Guimaracs FS. Wang M, Hcns-man R: Experimental tests of the 5HT receptor imbalance theory of affective disturbance: in Sandler M. Coppen A. Harnett S (eds): 5-Hydroxytryptamine in Psychiatry. Oxford, Oxford University Press, 1991. pp 143-154.
53. Costall B. Naylor RJ, Tyers MB: Recent advances in the neuropharmacology of 5HT3 antagonists and antagonists. Rev Neurosci 1988: 2:41-65.
54. Olivier B: Selective anti-aggressive properties of DU-27725: ethological analysis of intermale and territorial aggression in the male rat. Pharmacol Biochem Behav 1981:14(suppl 1):61-67.
55. Zohar J. Insel TR: Obsessive-compulsive disorders: Psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 1987;22:667-687.
56. Zak JP. Miller JA. Sheehan DV. Fanous BSL: The potential role of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder. J Clin Psychiatry 1988;49(suppl):23-30.
57. Zohar J. Mueller EA. Insel TR. Zohar-Ka-douch RC, Murphy DL: Serotonergic respon-sivity in obsessive-compulsive disorder: Comparison of patients and healthy controls. Arch Gen Psychiatry 1987;44:946-951.
58. Pato MT. Pigott TA. Hill JL. Grover G. Bernstein SE. Murphy DL: Clomipramine versus buspirone in OCD: A controlled trial. American Meeting of the American Psychiatric Association, San Francisco. 1989. abstr No. 14.
59. Baxter LR. Thompson JM, Schwartz JM: Trazodone treatment response in obsessive compliance disorder correlated with shifts in glucose metabolism in the caudate nucleus. Psychopathology 1987:20(suppl l):l 14-122.
60. Sheehan DV. Zak JP. Miller JA. Fanous BSL: Panic disorder: The potential role of serotonin rcuptake inhibitors. J Clin Psychiatry 1988: 49(suppl):30-36.
61. Butler J. Tannion M. O'Rourke D, Fahy TJ. Leonard BE: Functional changes in the adrenergic and serotonergic systems in patients with panic disorders: in Belmaker RH. Sandler M. Pahlstrom A (eds): Progress in Catecholamine Research. Part C: Clinical Aspects, 1988. pp 399-407.
62. Coplan JD. Walk SI. Kelin DF: Anxiety and the 5HT1A receptor: in Bloom FE. Kupfcr DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York. Raven Press, 1995. pp 1301-1310.
63. Hamon M. Ereit MB. El Mestikawy S. Verge D. Dava IG, Marquet A, Gozlan H: Pharmacological, biochemical and functional properties of 5HTIA binding sites labelled by 8-OH-DPAT in the rat brain: in Ahlenius CT. Hudson S, Hudson PH (eds): Brain 5HTIA Receptors. Chichester, Horwood. 1987. pp 34-51.
64. Ogren SO. Fuxe K: Effects of antidepressant drugs on cerebral serotonin receptors: in Green AR (ed): Neuropharmacology of Serotonin. London. Oxford University Press, 1985. pp 131-180.
65. Butler J. Tannian M. Leonard BE: The chronic effects of desiprantine and sertraline on platelet and synaptosomal 5HT uptake in olfactory bul-bectomized rats. Prog Neuropsychopharmacol Biol Psychiatry' 1988; 12:585-594.
66. Mealy D. Carney PA, Leonard BE: Mono-aminc-relatcd markers of depression: Changes following treatment. J Psychiatr Res 1983:17: 251-260.
67. Deak JFW. Guimaraes FS. Wang M. Hcns-rnan R: Experimental tests of the 5HT receptor imbalance theory of affective disturbance; in Sandler M. Coppen A, Harnett S (eds): 5-Hvdroxytryptaminc in Psychiatry. Oxford. Oxford University Press. 1991. pp 143-154.
68. Arora RC, Meltzer HY: Serotonergic measures in brains of suicide victims: 5HTR2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry' 1989:146: 730-736.
69. Stanley M, Mann JJ: Increased serotonin 2 binding sites in frontal cortex of suicide victims. Lancet 1983;i:214-216.
70. Chopin P, Moret C, Briley M: In vivo neuropharmacology of 5HTIB/D receptor ligands. Pharmacol Ther. in press.
71. Leonard BE: Biological markers of serotonin receptors in depression and animal models of depression. Int Rev Psychiatry 1995:7:69-83.
72. Cros AJ: Serotonin in neurodegenerativc disorders: in Osborne NN, Harmon M (eds): Neuronal Serotonin. Chichester. Wiley. 1988. pp 231-254.
73. Hartig PR: Molecular biology of 5HT receptors. Trends Pharmacol Sci 1989; 10:64-69.
74. Humphrey PPA. Hartig P, Hoycr D: A proposed new' nomenclature for 5HT receptors. Trends Pharmacol Sci 1993;14:233-236.
75. Rapport MM. Green AA. Page IH: Crystalline serotonin. Science 1948:108:329.